Skip to main content
. 2015 Jun 15;5(7):2139–2155.

Figure 5.

Figure 5

In vitro cytotoxicity of evofosfamide in combination with everolimus or temsirolimus in 786-O and Caki-1 RCC cells. A. Treatment schedule and experiment design. B and C. Evofosfamide alone, or combined with everolimus in 786-O and Caki-1 cells under either air (21% O2) or hypoxia (N2), respectively; D and E. Evofosfamide alone, or combined with temsirolimus in 786-O and Caki-1 cells under either air (21% O2) or hypoxia (N2). The viable cells were detected using AlamarBlue and quantified with microspectrofluorometry. The data are the representative of two independent experiments. Evo, evofosfamide; Eve, everolimus; and Tem, temsirolimus.